P. Saggu

The 5‐lipoxygenase‐activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma

B. O'connor, Z. Diamant, V. Norris, 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination

J. Lötvall, L. Bjermer, P. Thomas, 2013, Allergy.

A Repeat Dose, Double-Blind, Placebo-Controlled "Thorough QT/QTc Study" To Assess The Cardiac Safety Of Fluticasone Furoate (FF) And Vilanterol (VI) Administered In Combination

C. Crim, K. Kelly, R. Kempsford, 2012, ATS 2012.

Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials

C. Harrington, P. Patel, P. Benn, 2022, Journal of acquired immune deficiency syndromes.

A repeat-dose thorough QT study of inhaled fluticasone furoate/vilanterol combination in healthy subjects

C. Crim, K. Kelly, R. Kempsford, 2014, British journal of clinical pharmacology.